Voiant is the Imaging CRO partner of choice for BICR of respiratory imaging biomarkers.
As the new entity formed by the union of three industry leaders in clinical imaging, Voiant is the top solution that combines respiratory imaging expertise with the latest in AI-driven technology, enabling efficient clinical BICR reads to minimize adjudication rates and shorten time for data QC and lock. Together, we help our clients attain high quality imaging data for pulmonary device and drug trials—on time and on budget.
Respiratory Imaging Expertise
Voiant provides wide-ranging solutions for sponsors seeking the best data to support their drug and medical device trials. Our worldwide experience includes all trial phases, multiple pulmonary indications, and the analysis of a variety of advanced biomarkers.
Experience Across Respiratory Indications
With KOL led development of read paradigms including ATS/ERS and Fleischner Society criteria, Voiant has delivered imaging services on Phase I-IV drug and device trials across multiple obstructive and fibrotic lung indications, including:
- Acute and chronic sinusitis
- Allergic rhinitis
- Asthma (mild to severe – drug and medical device)
- Cystic fibrosis
- Lung cancer
- Pulmonary hypertension
- Upper and lower respiratory tract infections
We have extensive experience with AI driven advanced biomarkers like:
- Regional Lung Volumetrics
- Lung Density
- Airway Analytics, Fissure Integrity Score (FIS)
- Target Lobe Atelectasis Score (TLAS)
- Quantitative Lung Fibrosis (QLF)
- Quantitative Interstitial Lung Disease (QILD), which includes quantitation of honeycombing and ground glass
AI-Powered Excellence in
Respiratory Imaging Technology
Our software platform integrates AI support for semi-automated functions and consistency of reads to minimize adjudication rates and shorten time for data QC and lock. Our state-of-the-art systems are 21 CRF Part 11 compliant and are used to analyze images from all modalities. The systems can be accessed by radiologists to perform assessments anywhere in the world. Thousands of clinical sites in the U.S., Latin America, Europe, and Asia-Pacific have uploaded imaging data directly into our secure system.
Voiant’s technology platform uses AI technology to guide its users through key steps in image analysis:
- Enhancing volume
- Image QC
- PHI detection and removal
- Selection of best image(s) for analysis
Voiant’s fully configurable, highly scalable platform can be accessed anywhere, on any device, for scan tracking, adaptive reads, periodic reporting, and custom reader notifications.
Experience the future of imaging in clinical trials. Schedule an exploratory discussion to learn more about our solutions.